Tivorsan makes key DMD therapy development
Tivorsan Pharmaceuticals, a protein therapeutics firm in Providence, R.I., has shown that mice with Duchenne Muscular Dystrophy have had improved muscle function due to biglycan protein, according to a news release today from the company.
The company is preparing to bring the protein to human clinical studies.
Duchenne Muscular Dystrophy is a muscle loss disorder that affects one in 3,500 newborn boys, the company reported, and is marked by a mutation of the dystrophin protein-encoded gene. The disease has no current treatments available.